Metabolic & Cardiometabolic · Gut & Microbiome
secondary bile acids stimulates GLP-1
In plain terms: Do gut-bacteria bile acids boost your appetite-suppressing hormone GLP-1?
Yes as a mechanism, but only shown in animals so far — human evidence is correlational.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
How the studies fall
What the evidence shows
Microbe-generated secondary bile acids (DCA/LCA, taurine-conjugated) activate basolateral TGR5/GPBAR1 on L-cells to stimulate GLP-1 — robust in animal/ex-vivo models; the diet->microbe->secondary-BA->GLP-1 chain is causal in mice, human evidence is correlational only.
The evidence (16)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Meng Y, Li S, Zhou K, Suonan Z, Dai Z, Shen Q, Xue Y 2026 · Food chemistry | animal | mixed | moderate | Oat β-glucan raised gut secondary bile acids (LCA, DCA) in obese mice, which the authors show promote GLP-1 secretion 'via inhibiting FXR' — TGR5 is not invoked as the mediating receptor for the GLP-1 rise in this study. |
| Zhu X, Chen Z, Zhang B, Xie S, Wang M 2024 · Altern Ther Health Med | animal | supports | moderate | Bile acid injection lowered glucose in T2DM rats via TGR5/GLP-1 rather than the FXR/FGF15 pathway. |
| Lv J, Zhou L, Dai X, Landberg R, Meng H, Tian H, Zhang S, Liu T, Yin X, Zhang J, Song X, Bonny C, Blum S, Cao Y, Guo J, Peng W, Tan Y, Shi L 2026 · Gut microbes | animal | supports | moderate | L. salivarius XA1416 raised UDCA in mice, improving glucose/GLP-1. Oral UDCA replicated effect: acts as intestinal FXR antagonist + TGR5 (GPBAR1) agonist to stimulate GLP-1. HepG2 cells + molecular dynamics show UDCA directly activates GLP |
| Wang X, Zhang F, Zhang J, Du Y, Zhang T, Liu S, Di X 2026 · J Pharm Biomed Anal | animal | supports | moderate | Liuwei Dihuang upregulated ileal TGR5 and enhanced GLP-1/PYY secretion via gut-microbiota-bile-acid axis in T2DM rats. |
| Zheng X, Chen T, Jiang R, Zhao A, Wu Q, Kuang J, Sun D, Ren Z, Li M, Zhao M, Wang S, Bao Y, Li H, Hu C, Dong B, Li D, Wu J, Xia J, Wang X, Lan K, Rajani C, Xie G, Lu A, Jia W, Jiang C, Jia W 2021 · (HCA) | animal | supports | moderate | Zheng 2021 CellMetab hyocholic acids via TGR5+FXR mouse+human corr. ANIMAL/MECHANISM |
| Sun L, Jiang J, Zeng Y, Zhu J, Wang S, Huang D, Cao C 2024 · J Agric Food Chem | animal | supports | moderate | Mushroom polysaccharide raised conjugated ileal bile acids that stimulated TGR5, inducing GLP-1 release and better glucose metabolism. |
| Sun YH, Ding PL, Wang X, Wang YR, Zhu MZ, Wang K, Dai L, Dang YQ, Ji G, Li M, Zhou WJ 2026 · Pharmaceuticals (Basel, Switzerland) | animal | supports | low | Herbal formula LGZG in HFD mice enriched non-12α-OH secondary bile acids (hyocholic acid, 7-ketoLCA) — known TGR5 agonists/FXR antagonists — which elevated serum GLP-1 and activated adipose TGR5-cAMP/PKA/CREB signaling and thermogenesis. |
| Yue Z, Zhao F, Guo Y, Zhang Y, Chen Y, He L, Li L 2024 · Food & Function | animal | supports | moderate | TGR5 agonist INT-777 restored ileal TGR5/proglucagon expression and serum GLP-1 suppressed by acrylamide in mice. |
| Stefela A, Dohnalova K, Lastuvkova H, Skoda J, Bajnokova M, Lestavel S, Touche V, Kaspar M, Kudova E, Hroch M, Micuda S, Kucera O, Pavek P 2025 · Pharmacol Res | animal | supports | moderate | Dual FXR-antagonist/TGR5-agonist bile-acid analogue enhanced GLP-1 secretion and improved glucose homeostasis in Western-diet mice. |
| Zhang Y, Huang H, Wang Y, Li X, Hou P, Yu M, Zhang Z, Guo S, Liu C, Zhang Z, Zhuo Y, Zhu C, Zhang P, Wang S, Zhou H, Gan Y 2025 · Sci Transl Med | animal | supports | high | Intestinal TGR5-targeted deoxycholic-acid conjugate boosted GLP-1 secretion and glycemic control in mice and pigs. |
| Wang Q, Lin H, Shen C, Zhang M, Wang X, Yuan M, Yuan M, Jia S, Cao Z, Wu C, Chen B, Gao A, Bi Y, Ning G, Wang W, Wang J, Liu R 2023 · Gut Microbes | animal | supports | high | Gut-microbiota-derived ileal bile acids (wMCA, HCA) drive postprandial GLP-1 via TGR5, not FXR, in mice. |
| Yu H, Nie R, Shen C 2023 · Endocrine Journal | mechanism | supports | moderate | Narrative review: 'The present study reviews the metabolism and regulation of BAs'; 'This article aims to provide an overview of the molecular mechanisms', naming GLP-1 among BA signalling pathways. No new data — review, zero weight. |
| Pathak P, Xie C, Nichols RG, Ferrell JM, Boehme S, Krausz KW, Patterson AD, Gonzalez FJ, Chiang JYL 2018 · (FXR/TauroLCA) | animal | supports | moderate | Pathak/Chiang 2018 mouse microbiota+FXR activate TGR5 to improve metabolism. ANIMAL-only |
| Hui S, Huang L, Wang X, Zhu X, Zhou M, Chen M, Yi L, Mi M 2020 · FASEB J | animal | supports | moderate | Capsaicin raised lithocholic acid (LCA) via microbiota remodeling, an endogenous TGR5 agonist enhancing L-cell GLP-1 secretion. |
| Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ, Gribble FM, Reimann F 2015 · Endocrinology | mechanism | supports | moderate | Brighton/Gribble 2015 murine/ex-vivo L-cell BA->GLP-1 via basolateral TGR5. ANIMAL/MECHANISM-only |
| Ma H, Wu Y, Li D, Sun H, Xie Y, Zhao S, Guo W, Wang M, Cui R, Huang Y, Zhang X, Wan JY, Yao H, Yuan CS 2026 · Acta pharmaceutica Sinica. B | animal | supports | high | Obesity-prone humans/mice show depleted GDCA (secondary bile acid). GDCA supplementation in obese mice improved weight/steatosis and stimulated ileal GLP-1 secretion by activating TGR5 signaling, alongside BAT thermogenesis; FMT recapitulat |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.